Distinguished in Testicular Yolk Sac Tumor

Dr. Panagiotis A. Konstantinopoulos

Hematology Oncology | Hematology | Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
 (133.2 mi)
Accepting New Patients
Offers Telehealth
Distinguished in Testicular Yolk Sac Tumor
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
 (133.2 mi)
OverviewInsuranceLocationsClinical Research

Overview

Panagiotis Konstantinopoulos is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Konstantinopoulos and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Testicular Yolk Sac Tumor, and Ovarian Carcinosarcoma. Dr. Konstantinopoulos is currently accepting new patients.

His clinical research consists of co-authoring 138 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Testicular Yolk Sac Tumor.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Study Phase: Phase 1
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Alpelisib, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
Study Phase: Phase 3
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
A Phase 2, Two-stage, Study of Mirvetuximab Soravtansine (IMGN853) in Combination With Pembrolizumab in Patients With Microsatellite Stable (MSS) Recurrent or Persistent Endometrial Cancer (EC)
A Phase 2, Two-stage, Study of Mirvetuximab Soravtansine (IMGN853) in Combination With Pembrolizumab in Patients With Microsatellite Stable (MSS) Recurrent or Persistent Endometrial Cancer (EC)
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, IMGN853
Study Phase: Phase 2
RESOLVE: LetRozole AbEmaciclib CombinationS in EndOmetriaL and OVarian CancEr: a Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination with Metformin and Zotatifin
RESOLVE: LetRozole AbEmaciclib CombinationS in EndOmetriaL and OVarian CancEr: a Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination with Metformin and Zotatifin
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Drug
Study Drugs: Letrozole, Abemaciclib
Study Phase: Phase 2
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 05, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Axitinib
Study Phase: Phase 2
NeoVax With Nivolumab in Patients With Ovarian Cancer
NeoVax With Nivolumab in Patients With Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2024
Intervention Type: Drug, Biological, Procedure
Study Drugs: Nivolumab, NeoVax Personalized NeoAntigen Cancer Vaccine
Study Phase: Phase 1
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: April 26, 2023
Intervention Type: Drug
Study Drugs: Olaparib, Onalespib
Study Phase: Phase 1
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug
Study Phase: Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

138 Total Publications

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.
Journal: JCO precision oncology
Published: April 18, 2024
Similar Doctors
Distinguished in Testicular Yolk Sac Tumor
Dr. Susana M. Campos
Oncology | Hematology | Hematology Oncology
Distinguished in Testicular Yolk Sac Tumor
Dr. Susana M. Campos
Oncology | Hematology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susana Campos is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Campos and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, and Ovarian Carcinosarcoma. Dr. Campos is currently accepting new patients.

Distinguished in Testicular Yolk Sac Tumor
Dr. Carolyn N. Krasner
Hematology | Oncology
Distinguished in Testicular Yolk Sac Tumor
Dr. Carolyn N. Krasner
Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carolyn Krasner is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Krasner and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Salpingo-Oophorectomy. Dr. Krasner is currently accepting new patients.

Distinguished in Testicular Yolk Sac Tumor
Dr. Joyce F. Liu
Oncology | Hematology Oncology
Distinguished in Testicular Yolk Sac Tumor
Dr. Joyce F. Liu
Oncology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joyce Liu is an Oncologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Liu and is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, and Ovarian Cancer. Dr. Liu is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile